Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...
Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...
The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...